Alembic Pharma Reports Rs 1.85 Billion Profit In Q2, Revenue Rises To Rs 19.10 Billion

Robust International Growth Drives Quarterly Gains  

Alembic Pharmaceuticals Ltd has announced its Q2 FY2025–26 financial results, reporting a consolidated revenue of Rs 19.10 billion and a net profit of Rs 1.85 billion. The company attributed the performance to sustained momentum in its US generics business and improved product mix in specialty therapies.

The management highlighted that R&D investments and regulatory approvals in the US and Europe have begun to yield results, with new launches contributing to top-line growth. Domestic formulations also remained stable, supported by chronic therapy demand and field force expansion.

Major Takeaways  

• Q2 FY2025–26 consolidated revenue: Rs 19.10 billion  
• Net profit: Rs 1.85 billion  
• Growth led by US generics and specialty product launches  
• Continued investments in R&D and regulatory filings  
• Domestic business supported by chronic therapy portfolio  

Sources: BSE India, Moneycontrol, Business Standard, Alembic Pharmaceuticals Investor Filings